Ashishifa - 500, a coded unani drug is a combination of 18 varieties
of Unani herbs. Among the eighteen different herbs, Kasini is
one of the most important herb added in this formula. It is said
to be very useful in the maintainence of Kidney failure disease.
These herbs are identified and used by Dr. Hakeem S. Akbar Kausar,
Chief physician, Alkausar Unani Kidney Foundation, Vaniyambadi,
since the past 25 years in his medical practice.
A joint project was signed by the University of Madras and the
Al-kausar Unani Kidney Foundation, Vaniyambadi for a research
work on Ashshifa - 500 at the University Campus in the year 1995
in the Acute Renal Failure and chronic Renal failure.
Ashshifa the coded drug supplied by Al-kausar Unani Kidney Foundation,
Vaniyambadi for research work.
The research work was done for the period of five years form 1995
to 1999 in the Department of Bio-Chemistry & Molecular Biology,
University of Madras, Chennai.
The first research report on Acute Renal Failure was submitted
to Dr. Akbar Kausar, Director, AI-Kausar Unani Kidney Foundation
by Prof. P.T. Monoharan Vice-Chancellor, University of Madras
on 10-6-1998 in his Chamber congratulating and honouring Dr. S.
Akbar Kausar for his invention "ASHSHIFA-500".
Second research report on Chronic renal failure was submitted
to Dr. Akbar Kausar by Rev. Fr. Dr. Ignachimuthu, Vice-Chancellor,
University of Madras on 25.11.2002.
Our day to day exposure to drugs and chemicals has put increasing
demands on numerous organs of the body. Within these organs, the
response of any given cell or tissue to an insult caused by a
drug or chemical or it's metabolites is determined by the interplay
of many factors. Because the urinary system is involved in eliminating
toxic and waste substances, both drugs and chemicals may either
generally or selectively damage the urinary system as filtration
and excretion occur. Overt nephropathy, secondary to drug or chemical
exposure occurs frequently and accounts for aproximately 5% of
all nephrology consultations and 20% to 30 % of all cases of acute
TREATMENT OF RENAL FAILURE
the renal failure occurs, the more commonly adopted treatments
in recent years are 1. Dialysis and in severe cases 2. Transplantation.
Since dialysis and transplantation have got their own limitations
and drawbacks, search for new medicines, which cures kidney ailments,
without any side effects still continues.
ASHSHIFA -500 (UNANI FORMULATION)
Ashshifa-500 a coded drug by AI-Kausar Unani Kidney Foundation,
Vaniyambadi is a combination of herbs of 18 varieties and it is
claimed to have an antinephrotoxic potency against acute and chronic
GENTAMICIN -A POTENT NEPHROTOXIC AGENT
Gentamicin has been accepted as the antibiotic of choice in the
treatment of serious pseudomonas and proteus infections. But this
aminoglycoside shares the reputation of other aminoglycosides
such as streptomycin and kanamycin for being potentially nephro
& ototoxic. Rats treated with high dose gentamicin develop
monoliguric acute renal failure characterized by proximal tubular
necrosis, depression of GFR and proimal tubular dysfunction.
ACUTE RENAL FAILURE
In the present study, acute renal failure was induced transiently
in rats by administering moderate and high dosages of gentamicin
to decipher the antinephrotoxic potency of Ashshifa-500. Three
different concentrations of gentamicin 40mg/kg body weight twice
daily for 15 days, 200mg/kg body weight for 5 days, 400mg/kg body
weight for 5 days were used to induce acute renal failure.
CHRONIC RENAL FAILURE
Animals with chronic renal failure were prepared by feeding them
an 18% casein diet containing 0.75% adenine for 45 days. The animals
were treated with Ashshifa-500 from 30th day till 45 day with
a dose of 200mg/kg body weight thrice daily.
TREATMENT WITH ASHSHIFA -500
The effective dose of Ashshifa-500, to the treatment of renal
disease has been derived as 200mg/kg body weight.
Non protein nitrogenous waste products such as urea, creatinine
and uric acid which produce the clinical manifestation or uremia
in renal failure was assessed in the blood and urine of azotemia
animals before and after treatment with Ashshifa-500.
The elevated levels of uremic toxins were found to be reduced
in both the acute and chronic renal failure after treatment
with Ashshifa-500, due to the increased excretion of the same
in the urine.
• The effect of Ashshifa-500, on the accumulation of the
lipid peroxide induced MDA content in the renal cortex and the
activities of the free radical scavenging system such as SOD,
CAT, GST and the content of the total GSH was studied in both
acute & chronic renal failure groups.
• Significant increase in th levels of lipid peroxides
and decrease in the activities of the antioxidant
enzymes observed during renal failure was found to be partly
normalised after treatment with Ashshifa-500.
• Histological studies were carried out on the renal cortex
of acute chronic renal failure animals and compared with their
corresponding Ashshifa-500 treated groups, to confirm the curative
effect of Ashshifa-500 and its regenerative capacity towards
the necrotic kidney tissues.
• Increased percentage of renal tissue regeneration was
evident from the renal histology observed after treatment with
• The activities of the pathophysiological enzymes such
as LDH, SGOT, SGPT., acid phosphatase and alkaline phosphatase,
which would reflect the extent of tissue damage was assessed
in both serum and in the renal cortex of experimental animals.
• The regeneration was also evident from the results of
the pathophysiological enzymes which showed increased activities
in the renal tissues after treatment with Ashshifa-500.
• The extent of regeneration produced after treatment
with Ashshifa-500 was also assessed by measuring the activities
of the ion transporting and membrane bound enzymes such as Na+,
K+ ATPase, Ca2+ATPase and Mg2+ATPase in the tissue slices of
the renal cortex.
• The activities of ATPases in the kidney tissues were
found to be increased after treatment with Ashshifa-500.
• The activities of the citric acid cycle enzymes, which
are used as a measure of mitochondrial membrance integrity,
such as Succinate Dehydrogenase, Malate Oehydrogenase, NADH
Dehydrogenase, Cyt-C-oxidase, Isocitrate Dehydrogenase and &
- KG Dehydrogenase were also assayed in both acute and chronic
renal failure groups.
• The citric acid cycle enzyme were found to be increased
compared to the toxic groups after treatment with Ashshifa-500.
• Mitochondrial structural alterations observed during
renal failure were minimized after the treatment period with
• Mitochondrial oxygen uptake and respiratory control
ratio were examined by using biological oxygen electrode in
the experimental groups of acute and chronic renal failure.
• Ashshifa-500 produced an increased oxygen uptake and
RCR when compared to the corresponding toxic groups.
• Protein patterns for acute renal failure groups were
obtained by Poly Acrylamide Gel Electrophoresis (PAGE). Electrophoretic
studies revealed similar distribution pattern in Ashshifa -
500 and control groups.
• Severity of anemia was compared among the renal failure
groups. Anemia was found to be reduced after treatment with
• The correlation between protenuric renal diseases and
the hyperlipemia with corresponding alterations in the lipoprotein
patterns have been studied in the chronic group. The alternations
were brought back to near normal condition after treatment with
The glycoprotein levels such as Hexose, Hexosamine,
fucose and sialic acid were estimated
in the renal cortex of chronic experimental groups. The levels
were found to be decreased
during renal failure, but upon treatment with Ashshifa-500,
the decreased levels were found to